NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cardlytics, Inc. ("Cardlytics" or the "Company") (NASDAQ:CDLX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Cardlytics and certain of its officers and/or directors have engaged […]
After Tax NPV5% of US$111 Million at US$2,100/oz Au price After Tax NPV5% of US$153 Million at Spot prices 1 Average annual production targeted at approx. 56,000 Gold Equivalent Ounces ("GEO") 2 Life of Mine Average annual EBITDA of US$49 Million and FCF of US$25 Million LOM average EBITDA of US$64 Million and FCF of
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Arhaus, Inc. ("Arhaus" or the "Company") (NASDAQ:ARHS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Arhaus and certain of its officers and/or directors have engaged
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Warner Bros. Discovery, Inc. ("WBD" or the "Company") (NASDAQ:WBD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether WBD and certain of its officers and/or directors
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Metagenomi, Inc. ("Metagenomi" or the "Company") (NASDAQ:MGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Metagenomi and certain of its officers and/or directors have engaged
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Syros Pharmaceuticals, Inc. ("Syros" or the "Company") (NASDAQ:SYRS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Syros and certain of its officers and/or directors have
Trinity Capital Inc. (Nasdaq: TRIN) (“Trinity” or the “Company”), a leading provider of diversified financial solutions to growth-stage companies, today announced an increase to $510 million of total commitments under its credit facility led by KeyBank N.A. https://mma.prnewswire.com/media/2510476/Trinity_Capital_Logo.jpg The credit facility was expanded under the existing accordion feature by $70 million, bringing total commitments from
Affected communities installed an anti-monument and read a strong statement recollecting a decade of struggle for justice, reparations for environmental damage, urgent health care specialized in toxicology, and guaranteed access to clean and drinkable water. Contamination persists and the effects have worsened. The cost of the damages keeps increasing. MEXICO CITY, Sept. 19, 2024 (GLOBE
EMERYVILLE, Calif., Sept. 19, 2024 (GLOBE NEWSWIRE) — Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that company management will participate in the following events at Chardan’s 8th Annual Genetic Medicines Conference: Fireside chat on Monday, September 30, 2024,
HIGHLIGHTS — The US FDA has granted Fast Track Designation to Amplia’s lead drug narmafotinib in advanced pancreatic cancer — Fast Track Designation facilitates the development of investigational drugs and allows for expedited review Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), is pleased to announce that the United States Food and Drug Administration